Neogen (NEOG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Aug, 2026Executive summary
Annual meeting scheduled for October 1, 2026, with virtual participation available for shareholders.
Shareholders are encouraged to review proxy materials and vote by September 30, 2026, or September 28, 2026, for plan shares.
Voting matters and shareholder proposals
Election of three directors: Aashima Gupta, Raphael A. Rodriguez, and Catherine E. Woteki, Ph.D.
Advisory vote on the compensation of Named Executive Officers.
Ratification of BDO USA P.C. as the independent registered public accounting firm.
Approval of the Amended and Restated Omnibus Incentive Plan.
Approval of an amendment to the Employee Stock Purchase Plan.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director nominees and compensation plans.
Latest events from Neogen
- FY31 targets pair innovation-led growth with 30% adjusted EBITDA margin and ~80% FCF conversion.NEOG
Investor Day 2026 - Core growth and margin gains lifted FY27 guidance as the Petrifilm transition advanced.NEOG
Q1 2027 - All proposals passed with high approval, including director elections and plan amendments.NEOG
AGM 2026 - Correction increases ESPP share reserve to 6,000,000; Board recommends approval.NEOG
Proxy filing - Improved growth, leadership changes, and enhanced ESG drive key proxy proposals for 2026.NEOG
Proxy filing - Q4 core growth accelerated, margins improved, and FY27 guidance signals continued momentum.NEOG
Q4 2026 - Integration progress and international growth position the business for margin expansion and recovery.NEOG
2024 Wells Fargo Healthcare Conference - Q2 FY26 delivered 2.9% core growth, margin expansion, and a raised FY26 outlook.NEOG
Q2 2026 - Q2 revenue hit $230M as integration advances, margin initiatives progress, and global growth accelerates.NEOG
Piper Sandler 36th Annual Healthcare Conference